EUNOS, Budapest, Hungary

GenSight will present two posters on its lead gene therapy product GS010 to treat LHON. For both posters, details of the session are the followings :

Date & Time of the session: 12 September 2017, 12:30

  • GS010 – Phase I/II Clinical Trial Data after 78 Weeks of Follow-up

Scott Uretsky, MD, Neuro-Ophthalmology, Medical Director, will present ” Phase I/II Safety and Visual Acuity Outcomes 78-weeks post-treatment with rAAV2/2-ND4, an investigational gene therapy for ND4 LHON “. (Poster Number: PA68).

  • GS010 – RESCUE and REVERSE Phase III Clinical Trials Baseline Characteristics

Patrick Yu-Wai-Man, MD, international coordinating investigator of the REVERSE study and Honorary Consultant in Ophthalmology at the Moorfields Eye Hospital in London, and the Newcastle Hospital, United Kingdom, will present ” Preliminary Baseline Characteristics of Patients with Leber Hereditary Optic Neuropathy (LHON) Enrolled in the RESCUE and REVERSE  Phase III Clinical Gene Therapy Trials “. (Poster Number: PA81).